Literature DB >> 33733379

Impact of Behavioral Health Consultation on Hepatitis C Treatment Outcomes at a Federally Qualified Health Center; Philadelphia, PA.

Kaitlin Grosgebauer1, Tyler S Bartholomew2,3, Katherine Huynh4, Travis Cos4,5.   

Abstract

Hepatitis C virus (HCV) infection is a public health issue that claims the lives of 350,000 individuals globally every year. Primary care providers are increasingly prescribing HCV medications with more modern, simplified administrations. Individuals with HCV are disproportionately affected by behavioral health challenges and substance use disorders. Integrated behavioral health providers can work in concert with their patients' primary care teams to provide innovative treatment programs to help support the needs of HCV care. We used simple and multivariable logistic regression to determine the association between receipt of behavioral health consultation and two outcomes on the care continuum: insurance approval for treatment and initiated HCV treatment regimen. These models were fitted using theoretically hypothesized variables and multivariable regression models included age, sex, and race/ethnicity as potential confounders. From January 2015 to May 2017, 189 patients at health centers were referred for onsite HCV primary care treatment. Of these, 142 were approved for participation, and 132 started treatment. Simple regression revealed a significant association between behavioral health consultation and treatment approval; however, behavioral health consultation was non-significant in the multivariable model for treatment approval. For initiating HCV treatment, onsite behavioral health consultation was significantly associated in both the unadjusted and adjusted regression models. Integrating behavioral health services for patients seeking HCV treatment may improve movement across the care continuum, optimizing patient's HCV health outcomes. Behavioral health consultation in primary care settings should be studied further to improve HCV treatment outcomes for patients with behavioral health and substance use disorders.

Entities:  

Keywords:  Behavioral health; Drug policy; Hepatitis C; Mental illness; Primary care; Substance use

Year:  2021        PMID: 33733379     DOI: 10.1007/s10935-021-00627-2

Source DB:  PubMed          Journal:  J Prim Prev        ISSN: 0278-095X


  14 in total

Review 1.  Barriers to hepatitis C treatment.

Authors:  Christopher E McGowan; Michael W Fried
Journal:  Liver Int       Date:  2012-02       Impact factor: 5.828

Review 2.  Toward the elimination of hepatitis C in the United States.

Authors:  Sammy Saab; Long Le; Satvir Saggi; Vinay Sundaram; Myron J Tong
Journal:  Hepatology       Date:  2018-06       Impact factor: 17.425

3.  Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial.

Authors:  Sarah Kattakuzhy; Chloe Gross; Benjamin Emmanuel; Gebeyehu Teferi; Veronica Jenkins; Rachel Silk; Elizabeth Akoth; Aurielle Thomas; Charisse Ahmed; Michelle Espinosa; Angie Price; Elana Rosenthal; Lydia Tang; Eleanor Wilson; Soren Bentzen; Henry Masur; Shyam Kottilil
Journal:  Ann Intern Med       Date:  2017-08-08       Impact factor: 25.391

4.  Stages of change and decisional balance for 12 problem behaviors.

Authors:  J O Prochaska; W F Velicer; J S Rossi; M G Goldstein; B H Marcus; W Rakowski; C Fiore; L L Harlow; C A Redding; D Rosenbloom
Journal:  Health Psychol       Date:  1994-01       Impact factor: 4.267

5.  The Hepatitis C Virus Care Continuum: Linkage to Hepatitis C Virus Care and Treatment Among Patients at an Urban Health Network, Philadelphia, PA.

Authors:  Catelyn Coyle; Anne C Moorman; Tyler Bartholomew; Gary Klein; Helena Kwakwa; Shruti H Mehta; Deborah Holtzman
Journal:  Hepatology       Date:  2019-03-26       Impact factor: 17.425

6.  Barriers to the treatment of hepatitis C. Patient, provider, and system factors.

Authors:  James A Morrill; Melissa Shrestha; Richard W Grant
Journal:  J Gen Intern Med       Date:  2005-08       Impact factor: 5.128

Review 7.  The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment.

Authors:  Brian P Lam; Thomas Jeffers; Zahra Younoszai; Yousef Fazel; Zobair M Younossi
Journal:  Therap Adv Gastroenterol       Date:  2015-09       Impact factor: 4.409

8.  Barriers to Treatment Among New York City Residents with Chronic Hepatitis C Virus Infection, 2014.

Authors:  Andrea King; Katherine Bornschlegel; Nirah Johnson; Eric Rude; Fabienne Laraque
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

9.  Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?

Authors:  Mamta K Jain; Mae Thamer; George Therapondos; Mitchell L Shiffman; Onkar Kshirsagar; Christopher Clark; Robert J Wong
Journal:  Hepatology       Date:  2018-12-18       Impact factor: 17.425

10.  Chronic hepatitis C virus (HCV) disease burden and cost in the United States.

Authors:  Homie Razavi; Antoine C Elkhoury; Elamin Elbasha; Chris Estes; Ken Pasini; Thierry Poynard; Ritesh Kumar
Journal:  Hepatology       Date:  2013-05-06       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.